Brokerages Set Lantheus Holdings, Inc. (NASDAQ:LNTH) PT at $122.50

Lantheus Holdings, Inc. (NASDAQ:LNTH - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the nine ratings firms that are covering the stock, Marketbeat reports. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 1-year price target among analysts that have covered the stock in the last year is $122.50.

LNTH has been the subject of several research analyst reports. Redburn Atlantic assumed coverage on Lantheus in a research report on Tuesday, September 3rd. They set a "buy" rating and a $175.00 price target for the company. JMP Securities lowered their price objective on shares of Lantheus from $125.00 to $112.00 and set a "market outperform" rating for the company in a research note on Thursday, November 7th. StockNews.com downgraded shares of Lantheus from a "buy" rating to a "hold" rating in a research note on Thursday. Finally, Truist Financial reissued a "buy" rating and issued a $120.00 price target (down previously from $135.00) on shares of Lantheus in a research report on Friday, November 8th.

Lantheus Stock Performance

Shares of Lantheus stock traded up $0.44 on Monday, reaching $90.96. The company had a trading volume of 1,328,481 shares, compared to its average volume of 1,022,041. The firm's 50 day moving average price is $103.13 and its two-hundred day moving average price is $96.93. Lantheus has a 52-week low of $50.20 and a 52-week high of $126.89. The firm has a market cap of $6.32 billion, a PE ratio of 15.13 and a beta of 0.51.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. raised its stake in Lantheus by 5.6% during the 1st quarter. Vanguard Group Inc. now owns 7,362,969 shares of the medical equipment provider's stock worth $458,271,000 after acquiring an additional 389,828 shares in the last quarter. Janus Henderson Group PLC increased its position in shares of Lantheus by 7.7% during the third quarter. Janus Henderson Group PLC now owns 3,588,571 shares of the medical equipment provider's stock worth $393,844,000 after purchasing an additional 257,022 shares in the last quarter. Farallon Capital Management LLC boosted its position in shares of Lantheus by 53.7% in the 2nd quarter. Farallon Capital Management LLC now owns 2,279,227 shares of the medical equipment provider's stock valued at $182,999,000 after purchasing an additional 796,000 shares during the period. Geode Capital Management LLC grew its stake in Lantheus by 2.0% during the 3rd quarter. Geode Capital Management LLC now owns 1,683,500 shares of the medical equipment provider's stock worth $184,798,000 after buying an additional 32,551 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its stake in Lantheus by 1.6% in the second quarter. Dimensional Fund Advisors LP now owns 1,239,502 shares of the medical equipment provider's stock valued at $99,525,000 after buying an additional 19,071 shares during the last quarter. Hedge funds and other institutional investors own 99.06% of the company's stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.